RBC Capital Sees Mixed Q3 for Krystal Biotech as Vyjuvek Beats but Pipeline Readouts Slip
RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.
RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
Great news for DEB patients! VYJUVEK can now treat from birth and be applied at home by patients/caregivers. Plus, wound dressing changes are more flexible. These updates significantly improve convenience and quality of life, making it the standard treatment for all DEB wounds.